Compare ACADIA Pharmaceuticals Inc. (ACAD) vs CubeSmart (CUBE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs CubeSmart — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.69 (market cap $4.49B), while CubeSmart trades at $40.1 (market cap $9.26B). The key difference: CubeSmart is far larger — about 2.1× ACADIA Pharmaceuticals Inc.'s market cap, and CubeSmart pays a 5.19% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | CUBE | |
|---|---|---|
Market Cap | $4.49B | $9.26B |
Sector | Health | Real Estate |
52-Week High | $28.06 | $42.60 |
52-Week Low | $20.06 | $35.36 |
Enterprise Value | $3.69B | $12.75B |
Dividend Yield | — | 5.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
CubeSmart (CUBE) trades at $40.88, down 0.24% on the day, with a neutral technical signal and mixed earnings history. The company reported Q1 2026 EPS of $0.63, beating expectations, and maintains strong profitability with a 28.93% net income margin. Recent news highlights the upcoming Q2 2026 earnings release on July 30, 2026, and a declared dividend of $0.53 per share.
Outlook is balanced with a consensus price target of $43.17 suggesting modest upside, but risks include a high debt load and interest rate sensitivity. The stock offers a solid dividend yield, yet faces headwinds from macroeconomic uncertainty and competitive pressures in the REIT sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About CubeSmart
CubeSmart is a real estate investment trust that acquires, owns, and manages self-storage facilities throughout the United States. The company's real estate portfolio is composed of buildings with numerous enclosed storage areas for both residential and commercial customers to rent mainly on a month-by-month basis. Most of CubeSmart's facilities are located in Florida, Texas, California, New York, and Illinois. Cumulatively, these states account for both the majority of the square footage in the company's real estate portfolio and the majority of its revenue. CubeSmart derives nearly all of its revenue from rental income from tenants utilizing its storage facilities.
Read more on CUBE →
